Form 4 Apellis Pharmaceuticals, For: May 03 Filed by: Townsend Adam J.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Citi Comments on Apellis Pharmaceuticals (APLS), Moves PT to $106
May 5, 2023 11:15 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $106.00 (from $88.00) while maintaining a Buy rating.
The analyst comments "The first quarter of any drug launch is frequently a wildcard. Syfovre embodied this uncertainty given 1) mid-1Q23 approval, 2) temporary J-code,... More
